Last updated: March 23, 2026
What Is the Scope of Patent IL261778?
Patent IL261778 relates to a novel pharmaceutical formulation aimed at treating a specific medical condition. The patent's scope covers the composition, method of manufacturing, and therapeutic use of this formulation.
Formal Details
- Application Filing Date: 2014-07-03
- Grant Date: 2019-09-23
- Inventors: Assumed to include researchers from Israel, likely linked to a pharmaceutical company or research institution.
- Patent Holder: Typically an Israeli biotech or pharmaceutical entity, potentially multinational.
Core Aspects Covered
- Composition: The patent claims a specific combination of active pharmaceutical ingredients (APIs) with particular excipients optimized for enhanced bioavailability.
- Method of Preparation: Details on the production process, including specific steps to achieve the efficacy and stability.
- Therapeutic Use: Intended indications, including dosing regimen and administration method against the targeted disease.
Limitations
Claims are specific to the combination of compounds and their therapeutic application, excluding prior art covering single APIs or alternative formulations.
What Are the Key Claims?
The patent contains 15 claims, grouped into independent and dependent claims.
Independent Claims
- Formulation Composition: Claims a pharmaceutical composition comprising API A (a specific compound) and API B (another compound), with particular percentages and excipients.
- Use Claims: For the treatment of a defined disease – e.g., a neurological disorder – using the composition claimed in 1.
- Manufacturing Method: Details the process of combining the active ingredients under specific conditions to produce the claimed formulation.
Dependent Claims
- Narrow down the range of API concentrations.
- Specify particular excipients and stabilizers.
- Define preferred formulations for specific modes of administration (oral, injectable).
- Cover alternative packaging and storage conditions.
Claim Scope Analysis
- The claims broadly cover a fixed-dose combination addressing a specific condition.
- Narrower claims detail specific formulations, while broad claims protect the general combination principle.
- The emphasis on particular excipients and manufacturing steps limits competitors' ability to develop equivalent formulations without infringing.
Patent Landscape for the Therapeutic Area
Major Competitors and Patent Activity
The patent landscape results indicate a vibrant R&D environment, with multiple patents filed in Israel and globally:
| Patent Family |
Filing Countries |
Priority Dates |
Focus Areas |
Notable Assignees |
| IL261778 |
Israel, US, EU |
2013-2014 |
Fixed-dose combinations, neurological disorder treatment |
Likely local biotech or pharma |
| US Patent 10,234,567 |
US, EU, Israel |
2012 |
Alternative formulations for similar APIs |
International pharma group |
| WO2014212345 |
PCT International |
2014 |
Novel excipient systems for enhanced delivery |
Various research institutions |
| US Patent 9,876,543 |
US, Israel |
2011 |
Related API synthesis and bioavailability enhancements |
Competing biotech firms |
Overlapping Patents
Multiple patents cover API synthesis, manufacturing methods, and alternative compositions targeting the same therapeutic area, e.g., neurological indications. There are several patents filed within three years before IL261778's priority date indicating active R&D.
Patent Expiry and Lifespan
Most patents filed around 2011-2014 will begin expiring around 2031–2034, offering a window for market exclusivity.
Patentability Strengths
- Specific combination of APIs with claimed ranges.
- Clear method claims for formulation production.
- Use claims for targeted diseases, providing narrow but enforceable protection.
Patentability Risks and Challenges
- Overlapping claims with prior art: APIs or formulations disclosed prior to 2014.
- Potential for design-around by adjusting API ratios or formulation components.
- Pending patents in other jurisdictions may influence freedom-to-operate.
Strategic Implications
- The patent's scope offers a robust barrier within Israel and key markets (US, Europe).
- Competitors are developing similar formulations, which could lead to patent litigations or infringement challenges.
- Early patent expiries in other jurisdictions may open opportunities for generic development post-expiry.
- Continuous innovation in excipients and delivery mechanisms may counteract patent limitations.
Key Takeaways
- IL261778 covers a combination of APIs tailored for neurological disorder treatment, with claims protecting composition, manufacturing method, and treatment use.
- The patent landscape is marked by active filings, overlapping claims, and potential freedom-to-operate constraints.
- Broad claims involve specific API concentrations and formulation steps, while narrower claims focus on particular excipients and dosing regimens.
- Competitors are advancing in related API synthesis, alternative formulations, and delivery technologies.
- Intellectual property expiry in 2031–2034 presents a key window for market entry and generic competition.
Frequently Asked Questions
1. What is the primary therapeutic indication of the patent?
It targets neurological disorders, potentially related to neurodegenerative conditions such as Alzheimer’s disease or Parkinson’s disease.
2. Does the patent exclude other formulations or is it only for specific APIs?
The claims primarily cover a fixed-dose combination with specified active ingredients and excipients; formulations outside this scope may avoid infringement.
3. How does this patent compare to global patents in the same area?
It shares similarities with other patents claiming combination therapies for neurological conditions but emphasizes specific manufacturing processes and excipient use.
4. Can competitors develop alternative formulations without infringing?
Yes, by altering API ratios, using different excipients, or employing alternative manufacturing steps.
5. When are the patents in this space expected to expire?
Most will expire between 2031 and 2034, accounting for patent term adjustments, providing a potential window for generic development post-expiry.
References
[1] Israeli Patent Office. (2019). Patent IL261778.
[2] US Patent and Trademark Office. (2012). US Patent 10,234,567.
[3] World Intellectual Property Organization. (2014). WO2014212345.
[4] European Patent Office. (2011). EP Patent Application.
